Table 1.

Relation between 90K and initial patient characteristics

VariableN*90K levels
High (%)P
All patients 137 39  (28)  
Age (years)    
 ≤54 71 22  (31)  
 >54 66 17  (26) .24 
Gender    
 Male 77 20  (26)  
 Female 60 19  (32) .72  
Lactate dehydrogenase (U/l)    
 ≤284 62 14  (22)  
 >284 68 22  (32) .45  
Histologic subtype    
 B cell    
  DLCL 59 17  (29)  
  FL 26 6  (23)  
  IM 3  (50)  
  MCL 2  (40)  
 T cell    
  LL 4  (44) .13 
  Peripheral T-cell lymphoma 2  (28)  
  Anaplastic T-cell lymphoma 2  (50)  
Ann Arbor stage    
 I 18 7  (39)  
 II 21 5  (24)  
 III 33 9  (27) .28  
 IV 56 17  (30)  
Bone marrow involvement    
 Yes 35 14  (40)  
 No 85 22  (26) .06  
Bulky disease    
 Yes 28 6  (21)  
 No 100 32  (32) .14 
VariableN*90K levels
High (%)P
All patients 137 39  (28)  
Age (years)    
 ≤54 71 22  (31)  
 >54 66 17  (26) .24 
Gender    
 Male 77 20  (26)  
 Female 60 19  (32) .72  
Lactate dehydrogenase (U/l)    
 ≤284 62 14  (22)  
 >284 68 22  (32) .45  
Histologic subtype    
 B cell    
  DLCL 59 17  (29)  
  FL 26 6  (23)  
  IM 3  (50)  
  MCL 2  (40)  
 T cell    
  LL 4  (44) .13 
  Peripheral T-cell lymphoma 2  (28)  
  Anaplastic T-cell lymphoma 2  (50)  
Ann Arbor stage    
 I 18 7  (39)  
 II 21 5  (24)  
 III 33 9  (27) .28  
 IV 56 17  (30)  
Bone marrow involvement    
 Yes 35 14  (40)  
 No 85 22  (26) .06  
Bulky disease    
 Yes 28 6  (21)  
 No 100 32  (32) .14 

DLCL indicates diffuse large-cell lymphoma, 59 patients; FL, follicular lymphoma, 26 patients; IM, immunocytoma; 6 patients; MCL, mantle-cell lymphoma, 5 patients; LL, lymphoblastic lymphoma, 9 patients.

*

Information on all variables was not always available.

Number (percentage) of patients with 90K levels above the cutoff value of 13.5 μg/mL.

Close Modal

or Create an Account

Close Modal
Close Modal